Table 1 Baseline characteristics of the study population receiving intervention of a dietary supplementation of selenium and coenzyme Q10 combined during 4 years
| Â | Active | Placebo | p-value |
|---|---|---|---|
N | 118 | 101 | Â |
Age years mean (SD) | 76.2 (3.1) | 76.3 (3.1) | 0.74 |
Males/Females n | 58/60 | 43/58 | Â |
History | |||
 Diabetes n (%) | 20 (16.9) | 18 (17.8) | 0.87 |
 Hypertension n (%) | 81 (68.5) | 72 (71.3) | 0.67 |
 IHD n (%) | 22 (18.6) | 16 (15.8) | 0.59 |
 NYHA class I n (%) | 71 (60.2) | 58 (57.4) | 0.68 |
 NYHA class II n (%) | 29 (24.6) | 30 (29.7) | 0.39 |
 NYHA class III n (%) | 18 (15.3) | 12 (11.9) | 0.47 |
 NYHA class IV n (%) | 0 | 0 |  |
Medications | |||
 Anticoagulants n (%) | 9 (7.6) | 9 (8.9) | 0.73 |
 ACEI n (%) | 15 (12.7) | 14 (13.9) | 0.80 |
 ARB n (%) | 4 (3.4) | 7 (6.9) | 0.23 |
 Beta blockers n (%) | 44 (37.3) | 33 (32.7) | 0.48 |
 Digitalis n (%) | 5 (4.2) | 1 (0.9) | 0.14 |
 Diuretics n (%) | 39 (33.1) | 33 (32.7) | 0.95 |
 Statins n (%) | 27 (22.9) | 17 (16.8) | 0.27 |
Examinations | |||
 EF < 40% n (%) | 7 (5.9) | 4 (4.0) | 0.51 |
 Atrial fibrillation n (%) | 6 (5.1) | 7 (6.9) | 0.56 |
Lab | |||
 Hb < 120 g/L (%) | 11 (9.3) | 9 (8.9) | 0.92 |
 hsCRP g/L (SD) | 2.60 (2.60) | 5.60 (22.15) | 0.34 |